In this work, we devise a method for the detection of a nucleic acid called PCA3, approved by the US Food and Drug Administration (FDA) as a urinary biomarker for prostate cancer diagnosis [21], in combination with a personal glucose meter, and magnetic particles as a solid support for a sandwich-type genoassay, as depicted in Figure 1b. This evidence concerns the gene PCA3 and prostate carcinoma.